ADC Therapeutics Q3 Adj. EPS $(0.06) Beats $(0.21) Estimate, Sales $21.716M Beat $18.692M Estimate
Benzinga Newsdesk 2 hours ago
NewsEarningsEarnings Beats
ADC Therapeutics (NYSE:ADCT) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.21) by 71.43 percent. This is a 68.42 percent increase over losses of $(0.19) per share from
ADC Therapeutics (NYSE:ADCT) reported quarterly losses of $(0.06) per share which beat the analyst consensus estimate of $(0.21) by 71.43 percent. This is a 68.42 percent increase over losses of $(0.19) per share from the same period last year. The company reported quarterly sales of $21.716 million which beat the analyst consensus estimate of $18.692 million by 16.18 percent. This is a 32.20 percent increase over sales of $16.427 million the same period last year.